Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.
Ward, Natalie C; Page, Michael M; Watts, Gerald F.
Diabetes Obes Metab
; 21 Suppl 1: 52-62, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31002454
Diagnostico de hipobetalipoproteinemia en un nino de 8 años?
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.
Strategies for the use of nonstatin therapies.
2017 Taiwan lipid guidelines for high risk patients.
Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
What the guidelines do not say: statin non-benefit groups.
PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.